 |
32 Diseases |  |
4 Trials |
|
4 Trials |  |
140 News |  |
| 12» |
- ||| Tookad (padeliporfin) / ImPact Biotech
Trial completion date, Trial suspension, Trial primary completion date: Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (clinicaltrials.gov) - Oct 3, 2024
P1, N=36, Suspended, Sponsor: Impact Biotech Ltd
Trial completion date: Dec 2027 --> Dec 2028 | Not yet recruiting --> Suspended | Trial primary completion date: May 2026 --> May 2027
- Tookad (padeliporfin) / ImPact Biotech
Padeliporphin VTP Reverts NSCLC Orthotopic Tumors in Animal Models Into Highly Responsive to aPD1 Therapy (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1139;
Conclusions : Based on the immune landscape of the LLC tumors, timely synchronization of VTP and clinically used ICI was designed and found effective and safe for treatment of orthotopic NSCLC in mice. Similar exploration in the upcoming Phase 1 clinical trial of Padeliporfin-VTP in patients with peripheral lung cancer is expected to provide guidelines for new treatment protocols combining ICI and VTP.
- Tookad (padeliporfin) / ImPact Biotech
Phase 1 study to evaluate safety and preliminary efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in patients with locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (PDAC). (Hall A; Poster Bd #: 172a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3933;
Conversion of unresectable locally advanced pancreatic cancer to surgery is a critical unmet need. This phase I trial explores a novel approach to treat the tumor encasement enabling surgery.
- Tookad (padeliporfin) / ImPact Biotech
ENLIGHTED phase 3 study: Efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for treatment of low-grade upper tract urothelial cancer (LG UTUC). (Hall A; Poster Bd #: 309b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1787;
P1, P3
To date Padeliporfin VTP has shown evidence of safety and efficacy with preliminary data that is consistent with prior experience. Recruitment for the ENLIGHTED trial is ongoing with results expected to provide basis for approval of a new therapy that clinically benefits pts.
- ||| Tookad (padeliporfin) / ImPact Biotech
Trial primary completion date: UCM301: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov) - Mar 17, 2024
P3, N=100, Recruiting, Sponsor: Steba Biotech S.A.
Recruitment for the ENLIGHTED trial is ongoing with results expected to provide basis for approval of a new therapy that clinically benefits pts. Trial primary completion date: Feb 2024 --> Dec 2024
- Tookad (padeliporfin) / ImPact Biotech
Efficacy and safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC): Phase 3 preliminary results (303A) - Mar 12, 2024 - Abstract #AUA2024AUA_1843;
P1, P3
Padeliporfin VTP has shown evidence of safety and efficacy with preliminary data that is consistent with prior experience. Recruitment for the ENLIGHTED trial is ongoing with results expected to provide basis for approval of a new therapy that clinically benefits pts.
- Tookad (padeliporfin) / ImPact Biotech
RESULTS OF THE PCM-204 PHASE 2B TRIAL OF PARTIAL-GLAND ABLATION FOR MEN WITH INTERMEDIATE-RISK PROSTATE CANCER WITH PADELIPORFIN (WST11 OR TOOKAD) VASCULAR-TARGETED PHOTODYNAMIC THERAPY (303B) - Mar 12, 2024 - Abstract #AUA2024AUA_1773;
Continued follow-up to the protocol defined 5-year endpoint is pending. Based on this data, this therapy bears consideration for approval as a conservative therapeutic option for selected cases of intermediate risk disease.
- Tookad (padeliporfin) / ImPact Biotech
aPD1 treatment of urothelial cancers is synergistically enhanced by activating anti tumor immunity using vascular targeted photodynamic therapy (Section 1) - Mar 5, 2024 - Abstract #AACR2024AACR_9464;
These observations indicate that elevating the content of anti-tumor immune cells in the tumor microenvironment by VTP in combination with ICI synergistically enhances the therapeutic effect providing a much higher complete cure compared with the individual therapies. The cure rate extent strongly depends on the synchronization of the two modalities providing guidelines for the clinical management of HG-UTUC treatment.
- || Tookad (padeliporfin) / ImPact Biotech
Trial completion date, Trial initiation date, Trial primary completion date: Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (clinicaltrials.gov) - Mar 5, 2024
P1, N=36, Not yet recruiting, Sponsor: Impact Biotech Ltd
The cure rate extent strongly depends on the synchronization of the two modalities providing guidelines for the clinical management of HG-UTUC treatment. Trial completion date: Dec 2026 --> Dec 2027 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2026
- || Tookad (padeliporfin) / ImPact Biotech
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 5, 2024
P1, N=30, Not yet recruiting, Sponsor: Impact Biotech Ltd
Trial completion date: Dec 2026 --> Dec 2027 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2026 Trial completion date: Oct 2025 --> Oct 2026 | Initiation date: Oct 2023 --> Apr 2024 | Trial primary completion date: Oct 2024 --> Apr 2025
- | Tookad (padeliporfin) / ImPact Biotech
Enrollment closed, Trial completion date, Trial primary completion date: Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov) - Dec 14, 2023
P1, N=30, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Oct 2025 --> Oct 2026 | Initiation date: Oct 2023 --> Apr 2024 | Trial primary completion date: Oct 2024 --> Apr 2025 Completed --> Active, not recruiting | Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Dec 2024
- | Tookad (padeliporfin) / ImPact Biotech
Trial completion, Trial completion date, Trial primary completion date: Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov) - Oct 3, 2023
P1, N=30, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Completed --> Active, not recruiting | Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Dec 2024 Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Oct 2023 | Trial primary completion date: Aug 2024 --> Oct 2023
- Tookad (padeliporfin) / ImPact Biotech
A novel approach to convert non-resectable pancreatic cancer with major artery involvement using endovascular activation of Padeliporfin by vascular-targeted photodynamic therapy (Level 2, Exhibit Hall D) - Sep 22, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_708;
- | Tookad (padeliporfin) / ImPact Biotech
New P1 trial: Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (clinicaltrials.gov) - Jun 26, 2023
P1, N=36, Not yet recruiting, Sponsor: Steba Biotech S.A.
- | Tookad (padeliporfin) / ImPact Biotech
New P1 trial, Metastases: Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 26, 2023
P1, N=30, Not yet recruiting, Sponsor: Steba Biotech S.A.
- | Tookad (padeliporfin) / ImPact Biotech
Enrollment closed, Trial completion date, Trial primary completion date: A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov) - May 24, 2023
P1, N=12, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Oct 2023 | Trial primary completion date: Aug 2024 --> Oct 2023 Completed --> Active, not recruiting | Trial completion date: Feb 2023 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Feb 2025
- Tookad (padeliporfin) / Steba Biotech
A phase 3 multicenter study to evaluate the safety and efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in treatment of low-grade (LG) upper tract urothelial cancer (UTUC). (On Demand | Hall A; Poster Bd # 99a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2113;
P1, P3
DSMB last reviewed the trial in Sep 2022 and suggested the trial continue as planned. Clinical trial information: NCT04620239.
- Tookad (padeliporfin) / Steba Biotech
WST-11 vascular-targeted photodynamic therapy induced immune modulation in upper tract urothelial cancer (Section 3; Poster Board #21) - Mar 14, 2023 - Abstract #AACR2023AACR_5399;
However, the MDSC level returned close to pretreatment level in the majority of cases. The frequency of CD8 T cells among the total (CD3 positive) T cells in PBMC was increased immediately after VTP in both CR and PR.
- | Tookad (padeliporfin) / ImPact Biotech
Trial completion: A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov) - Feb 27, 2023
P1, N=12, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
The frequency of CD8 T cells among the total (CD3 positive) T cells in PBMC was increased immediately after VTP in both CR and PR. Active, not recruiting --> Completed
- || Tookad (padeliporfin) / Steba Biotech
P1 data, Journal: Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-Targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma. (Pubmed Central) - Feb 2, 2023
P1, P3
VTP with WST-11 has an acceptable safety profile with strong potential as an effective, kidney-sparing endoscopic management option for UTUC. The recently initiated multi-center phase 3 ENLIGHTED trial (NCT04620239) is expected to provide further evidence on this therapy.
- ||| Tookad (padeliporfin) / ImPact Biotech
Trial completion date, Trial primary completion date: UCM301: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov) - Dec 20, 2022
P3, N=100, Recruiting, Sponsor: Steba Biotech S.A.
The recently initiated multi-center phase 3 ENLIGHTED trial (NCT04620239) is expected to provide further evidence on this therapy. Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2023 --> Feb 2024
- | Tookad (padeliporfin) / ImPact Biotech
Enrollment closed, Enrollment change: A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov) - Oct 26, 2022
P1, N=12, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2023 --> Feb 2024 Recruiting --> Active, not recruiting | N=24 --> 12
- || Tookad (padeliporfin) / Steba Biotech
Review, Journal: Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges. (Pubmed Central) - Oct 12, 2022
Herein, the latest research advances of newly developed photo/sonosensitizers for the treatment of urological cancers, and the efficacy, as well as potential biological effects, are highlighted. In addition, the clinical status of PDT/SDT for urological cancers is presented, and the optimization of the photo/sonosensitizer development procedure for clinical translation is discussed.
- | Tookad (padeliporfin) / Steba Biotech
Journal: Excimer laser-assisted corneal epithelial pattern ablation for corneal cross-linking. (Pubmed Central) - May 12, 2022
The different safety profile of near-infrared (NIR) may allow safe WST11/NIR CXL even with reduced stromal chromophore concentration values. In vivo studies are needed to evaluate the benefits and further assess safety of excimer laser-assisted patterned de-epithelialization for corneal CXL.
- | Tookad (padeliporfin) / ImPact Biotech
Trial completion date, Trial primary completion date: A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov) - May 5, 2022
P1, N=30, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
In vivo studies are needed to evaluate the benefits and further assess safety of excimer laser-assisted patterned de-epithelialization for corneal CXL. Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Apr 2023
- | Tookad (padeliporfin) / ImPact Biotech
Trial completion date, Trial primary completion date: Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov) - Apr 25, 2022
P1, N=30, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Apr 2023 Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
- Tookad (padeliporfin) / Steba Biotech
Final Results of a Phase I Trial of WST11 (TOOKAD Soluble) Vascular-Targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma (Room 252) - Apr 10, 2022 - Abstract #AUA2022AUA_3084;
Conclusions : This clinical trial provides necessary data on light dosing and treatment effects to establish safe treatment conditions with WST-11 VTP for UTUC. An approved Phase 3, multicenter trial with Society of Urologic Oncology-Clinical Trials Consortium support is upcoming.
- || Stakel (padeliporfin) / Steba Biotech, TLD-1433 / Theralase
Clinical, Journal: Clinical Development of Metal Complexes as Photosensitizers for Photodynamic Therapy of Cancer. (Pubmed Central) - Feb 11, 2022
In an effort to overcome these drawbacks, much attention has been devoted towards the incorporation of a metal ion. Herein, the clinical development of metal containing compounds including Purlytin ® , Lutrin ® /Antrin ® , Photosens ® , TOOKAD ® soluble or TLD-1433 is critically reviewed.
- | Stakel (padeliporfin) / Steba Biotech
Preclinical, Journal: Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer. (Pubmed Central) - Dec 16, 2021
After urothelial tumor implantation and 17 days before surgical resection, mice received neoadjuvant sbVTP (WST11; Tookad Soluble, Steba Biotech, France)...In summary, neoadjuvant sbVTP delayed local and systemic progression, prolonged progression-free and overall survival, and reduced local recurrence, thereby demonstrating therapeutic efficacy through an immune-mediated response. These findings strongly support its evaluation in clinical trials.
- Stakel (padeliporfin) / Steba Biotech
Investigating the multi-modality anti-tumour effects of combined sequential tumour irradiation and vascular-targeted photodynamic therapy in preclinical prostate cancer. ([VIRTUAL]) - Nov 16, 2021 - Abstract #NCRI2021NCRI_278;
We investigated whether sequential delivery of 3x5 Gy FRT followed by VTP (at 7-9 mg/kg WST-11) 7 days later improved tumour control compared to monotherapy with FRT or VTP alone...Further research aims to identify potential mechanisms of co-operation between these two treatments, with the aim of harnessing anti-tumour immunological responses. Impact statement This pre-clinical data provides first proof-of-concept for this multi-modality treatment, and may help to inform the design of future early phase clinical trials.
- ||| Tookad (padeliporfin) / ImPact Biotech
Trial completion date, Trial primary completion date: UCM301: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov) - Oct 20, 2021
P3, N=100, Recruiting, Sponsor: Steba Biotech S.A.
Impact statement This pre-clinical data provides first proof-of-concept for this multi-modality treatment, and may help to inform the design of future early phase clinical trials. Trial completion date: Jul 2024 --> Jan 2028 | Trial primary completion date: Jul 2022 --> Jan 2023
- Foscan (temoporfin) / American BriVision, Stakel (padeliporfin) / Steba Biotech
[VIRTUAL] Investigation of a novel class of aluminum tris-dipyrrinato complexes as potential photosensitizers (Room: Zoom Room 15) - Aug 13, 2021 - Abstract #ACSFall2021ACS_Fall_6221;
Subsequently, we will focus on the photophysical properties upon photoexcitation and the influence of the metal coordination center. In addition, we intend to investigate the electronic effects of the withdrawing or donating groups to the dipyrrin core; the singlet or triplet intraligant state ability; their emissive properties; and their triplet excited states properties.
- Stakel (padeliporfin) / Steba Biotech
[VIRTUAL] Results of the PCM-204 Phase 2b Trial of Partial-Gland Ablation for Men with Intermediate-Risk Prostate Cancer with Padeliporfin (WST11 or Tookad) Vascular-Targeted Photodynamic Therapy () - Aug 5, 2021 - Abstract #AUA2021AUA_2763;
These positive trial results show that WST11-VTP is effective for PGA of intermediate-risk prostate cancer with minimal toxicity including impact on urinary and sexual function, consistent with the Phase 3 trial results in low-risk disease. Based on these data this therapy bears consideration for approval as a conservative therapeutic option for selected cases of intermediate risk disease.
- Stakel (padeliporfin) / Steba Biotech
[VIRTUAL] Updated Treatment Results from a Phase I study of WST11 Phototherapy (VTP) for Upper Tract Urothelial Carcinoma. () - Aug 5, 2021 - Abstract #AUA2021AUA_2601;
WST11-VTP shows promising evidence of therapeutic treatment effect in low- and high-grade upper tract urothelial tumors with limited treatment related toxicity. These early results provide support for further investigation to evaluate the curative potential for this therapy in a planned multicenter trial.
- Stakel (padeliporfin) / Steba Biotech
[VIRTUAL] Intermittent WST-11 Vascular Target Photodynamic Therapy in a Mouse Orthotopic Bladder Model (Bellini 2104) - Aug 5, 2021 - Abstract #AUA2021AUA_2465;
Intermittent VTP treatment has an effect on mouse bladder tumors as shown by the decrease in tumor size, weight and change in histology. Additional refinement to the model may provide a means to establish an appropriate timeline and utility for future studies.
- | Stakel (padeliporfin) / Steba Biotech
Journal: Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment. (Pubmed Central) - Aug 5, 2021
VTP induced minimal changes in erectile function with a 3-point and a 1-point reduction in the IIEF5 score at 6 months and at 1 year, respectively. When required, ED treatment was efficient.
- Stakel (padeliporfin) / Steba Biotech
[VIRTUAL] TARGET VASCULAR PHOTODYNAMIC THERAPY AS A TREATMENT OF UPPER TRACT UROTHELIAL TUMOR () - Jul 2, 2021 - Abstract #ICUC2021ICUC_408;
However, the application of phototherapy has remained limited due to technical complexity, implementation, dosimetry and undesirable effects. The development of new, more selective photosensitizers and enhancement protocols can increase the oncological effectiveness of the technique.
- || Stakel (padeliporfin) / Steba Biotech
Review, Journal: Photodynamic therapy for prostate cancer- a narrative review. (Pubmed Central) - May 15, 2021
The mechanism and clinical methods of PDT application and the key points from clinical trials using PDT for prostate cancer with the photosensitizers m-tetrahydroxyphenyl chloride, protoporphyrin IX, motexafin lutetium, padoporfin, and padeliporfin between the years 2002 and 2017 are reviewed. Recently developed methodologies for photodynamic prostate cancer treatment that are in the experimental stage, photodynamic diagnosis, fluorescence guided resection, and PSMA-targeted PDT will also be discussed.
- | Tookad (padeliporfin) / ImPact Biotech
Trial completion date, Trial primary completion date: A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov) - May 5, 2021
P1, N=30, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recently developed methodologies for photodynamic prostate cancer treatment that are in the experimental stage, photodynamic diagnosis, fluorescence guided resection, and PSMA-targeted PDT will also be discussed. Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
- Stakel (padeliporfin) / Steba Biotech
[VIRTUAL] Phase 2b trial results of padeliporfin (WST11 or Tookad) vascular-targeted photodynamic therapy for partial gland ablation in men with intermediate-risk prostate cancer. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4507;
P2
The positive results from this trial show that WST11-VTP is effective for PGA of intermediate-risk prostate cancer, with minimal toxicity or impact on urinary and sexual function, consistent with the phase 3 trial results in low-risk disease . Based on these data, this therapy bears consideration for approval as a conservative therapeutic option for selected cases of intermediate-risk disease.
- | Tookad (padeliporfin) / ImPact Biotech
Enrollment closed: Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov) - Apr 22, 2021
P1, N=30, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Based on these data, this therapy bears consideration for approval as a conservative therapeutic option for selected cases of intermediate-risk disease. Recruiting --> Active, not recruiting
- || Stakel (padeliporfin) / Steba Biotech
Review, Journal: Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies. (Pubmed Central) - Apr 7, 2021
Vascular-targeted PDT (VTP) using padeliporfin, which is a water-soluble chlorophyll derivative, allows for tumor-specific cytotoxicity and has demonstrated efficacy in the management of urologic malignancies. Herein, we describe the evolution of photodynamic therapy in urologic oncology and the role of VTP in emerging treatment paradigms.
- |||| Tookad (padeliporfin) / ImPact Biotech
Enrollment open: UCM301: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov) - Mar 28, 2021
P3, N=100, Recruiting, Sponsor: Steba Biotech S.A.
Herein, we describe the evolution of photodynamic therapy in urologic oncology and the role of VTP in emerging treatment paradigms. Not yet recruiting --> Recruiting
- || Tookad (padeliporfin) / ImPact Biotech
Trial completion date: UCM301: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov) - Mar 22, 2021
P3, N=100, Not yet recruiting, Sponsor: Steba Biotech S.A.
Not yet recruiting --> Recruiting Trial completion date: Jun 2023 --> Jul 2024
- | Tookad (padeliporfin) / ImPact Biotech
Trial completion date, Trial primary completion date: Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov) - Feb 9, 2021
P1, N=30, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Jun 2023 --> Jul 2024 Trial completion date: Aug 2021 --> Aug 2023 | Trial primary completion date: Aug 2021 --> Aug 2023
- Stakel (padeliporfin) / Steba Biotech
[VIRTUAL] Treatment results from a phase I study of WST11 phototherapy (VTP) for upper tract urothelial carcinoma. () - Jan 8, 2021 - Abstract #ASCOGU2021ASCO_GU_603;
P1
WST11-VTP shows promising evidence of therapeutic treatment effect in low- and high-grade upper tract urothelial tumors with limited treatment related toxicity. These early results provide support for further investigation to evaluate the curative potential for this therapy in a planned multicenter trial.
- || Stakel (padeliporfin) / Steba Biotech
Hoeveel mensen moeten er extra overlijden door jullie keuze? Hoe moeilijk kan het zijn, een spuit zetten? Doe niet of er onoverkomelijke obstakels zijn. (Twitter) - Jan 5, 2021
- | Stakel (padeliporfin) / Steba Biotech
Journal: The effect of bacteriochlorophyll derivative WST-D and near infrared light on the molecular and fibrillar architecture of the corneal stroma. (Pubmed Central) - Dec 16, 2020
A cross-linking technique involving application of Bacteriochlorophyll Derivative WST-11 mixed with dextran (WST-D) to the epithelium-debrided cornea and illumination with Near Infrared (NIR), has been identified as a promising therapy for stiffening pathologically weakened corneas...Similarly, electron microscopy images of the anterior and posterior stroma in healed WST-D/NIR corneas and untreated controls revealed no obvious differences in collagen organisation or fibril diameter. As the size and organisation of stromal collagen is closely associated with the optical properties of the cornea, the absence of any large-scale changes following treatment confirms the potential of WST-D/NIR therapy as a means of safely stiffening the cornea.
- | Tookad (padeliporfin) / Steba Biotech
Enrollment change, Trial withdrawal: Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer (clinicaltrials.gov) - Nov 13, 2020
P3, N=0, Withdrawn, Sponsor: Steba Biotech S.A.
As the size and organisation of stromal collagen is closely associated with the optical properties of the cornea, the absence of any large-scale changes following treatment confirms the potential of WST-D/NIR therapy as a means of safely stiffening the cornea. N=400 --> 0 | Not yet recruiting --> Withdrawn
- |||||||| Tookad (padeliporfin) / ImPact Biotech
New P3 trial: UCM301: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov) - Nov 5, 2020
P3, N=100, Not yet recruiting, Sponsor: Steba Biotech S.A.